32
Views
1
CrossRef citations to date
0
Altmetric
Correspondences

The failure of torcetrapib: is there a case for independent preclinical and clinical testing? – correspondence

Response to: Doggrell SA. The failure of torcetrapib: is there a case for independent preclinical and clinical testing? Expert Opin Pharmacother 2008;9(6):875-78

, DrPH FAHA
Pages 2561-2562 | Published online: 08 Sep 2008

Bibliography

  • Doggrell SA. The failure of torcetrapib: is there a case for independent preclinical and clinical testing. Expert Opin Pharmacother 2008;9:875-878
  • Tardif JC, Heinonen T, Orloff D, Libby P. Vascular biomarkers and surrogates in cardiovascular disease. Circulation 2006;113:2936-42
  • Avorn J. Torcetrapib and Atorvastatin – Should Marketing Drive the Research Agenda? N Engl J Med 2005;352:2573-6
  • Shear CL. Torcetrapib and Atorvastatin [letter]. N Engl J Med 2005;353:1527
  • Barter P, Caulfield M, Eriksson M, et al. Effects of torcetrapib on morbidity and mortality in the ILLUMINATE trial. N Engl J Med 2007;357:2109-22
  • DePasquale M, Knight D, Loging W, et al. Mechanistic studies of hemodynamics with a series of cholesterol ester transfer protein inhibitors [abstract 4021]. Circ Res 2007;101(11):1209-10

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.